GO
| HSI1 | 24,498.95 | -18.81 | 236.41B |
| HSCEI1 | 8,853.10 | -8.29 | 74.68B |
| Back Zoom + Zoom - Block Traded | |
|
2025-07-17 12:26:50 The Shanghai Sunshine Pharmaceutical Procurement Platform recently issued a Notice Regarding the Commencement of Data Filing Work for the 11th Batch of National Centralized Drug Procurement, and launched the data submission process for 55 drugs, which will be included in the 11th batch of national centralized drug procurement (VBP), JPMorgan released a research report saying. Given recent policy discussions aimed at preventing involution and optimizing the 'lowest price wins' approach, as well as the relatively small number of 'big drugs' in this VBP, the broker expected the price reduction in the 11th batch of VBP to be relatively moderate, gradually reducing the impact on large Chinese pharmaceutical companies. The estimated market size for the 55 selected varieties in 2024 amounted to RMB50 billion, according to EMED data. The notice includes a list of 68 products that 'passed the evaluation but were not included', with reasons such as unresolved patent disputes, insufficient clinical safety evaluations and supply stability issues, indicating that the 11th batch of VBP emphasizes intellectual property and clinical value, JPMorgan noted. The broker believed that this disclosure of exclusion criteria implies an unprecedented level of transparency in the national drug procurement process, and will help to improve the predictability and transparency of future VBP, facilitating manufacturers' decision-making ~ AASTOCKS Financial News Website: www.aastocks.com | |